Advertisement
Canada markets open in 2 hours 30 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7297
    -0.0005 (-0.06%)
     

  • CRUDE OIL

    81.72
    -0.18 (-0.22%)
     

  • Bitcoin CAD

    90,830.77
    +273.34 (+0.30%)
     

  • CMC Crypto 200

    1,425.14
    +10.38 (+0.73%)
     

  • GOLD FUTURES

    2,318.00
    -28.40 (-1.21%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • NASDAQ futures

    17,404.75
    +54.75 (+0.32%)
     

  • VOLATILITY

    16.62
    -0.32 (-1.89%)
     

  • FTSE

    8,067.83
    +43.96 (+0.55%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6845
    -0.0005 (-0.07%)
     

Monopar to Present at the H.C. Wainwright BioConnect Conference

Monopar Therapeutics Inc.
·1 min read

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET.

Presentation Details:

Date: Monday, January 10, 2022

Time: 7:00am ET

Location: Virtual

https://hcwevents.com/

About Monopar Therapeutics Inc.

ADVERTISEMENT

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics